Abstract 104P
Background
A growing amount of data has indicated the possibility that tumor location may play a prognostic role in colon cancer. The present study set out to investigate the relation between the location of colon cancer (right side vs. left side) and the patient’s oncologic outcome.
Methods
This retrospective chart review studied 654 colon cancer patients who had been treated and followed up on at three tertiary hospitals between 2010 and 2015. To determine the most important independent factors of oncologic outcomes, the Cox regression multivariate analysis model used to analyze the prognostic impact of the primary tumor location and other clinical-, pathologic-, and treatment-related factors.
Results
In the univariate analysis, the prognostic factors for disease-free survival (DFS) were the primary tumor stage (< 0.001), node stage (<0.001), tumor grade (P = 0.013), surgical margin status (P = 0.001), lymphatic vascular invasion (LVI) (<0.001), and perineural invasion (PNI) (<0.001). Additionally, the prognostic factors for disease-free survival (OS) were the primary tumor stage (<0.001), node stage (<0.001), tumor grade (P = 0.036), presence of LVI (<0.001), presence of PNI (<0.001), and the mucinous type (P = 0.042). However, in the multivariate analysis, the presence of LVI, T3-4 lesions, tumor grade II-III, and an advanced disease stage remained independent prognostic factors for DFS as well as OS. However, the colon cancer location was not prognostic factor in terms of DFS or OS.
Conclusions
Although right-sided colon cancers present more aggressive clinical features, tumor location is not a significant prognostic factor for DFS and OS in colon cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The present study was approved by the University Research Ethics Committee and all procedures were performed in accordance with the ethical standards of the National Research Committee and with the Helsinki Declaration.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract